Browse > Article

Electrospray Tandem Mass Spectrometry for the Quantification and Bioavailability Test of Gliquidone in Human Plasma  

Moon Chul-Jin (Institute of Metabolism, Green Cross Reference Laboratory)
Lee Eun-Hee (Institute of Metabolism, Green Cross Reference Laboratory)
Yang Song-Hyun (Institute of Metabolism, Green Cross Reference Laboratory)
Moon Hae-Ran (Institute of Metabolism, Green Cross Reference Laboratory)
Publication Information
YAKHAK HOEJI / v.49, no.3, 2005 , pp. 212-216 More about this Journal
Abstract
A rapid, sensitive and selective electrospray tandem mass spectrometric (ESI-LC/MS/MS) method for the quantitation of gliquidone in human plasma was developed. A bioavailability study of gliquidone tablet (30 mg gliquidone, Boehringer Ingelheim Korea Co.) was performed using the validated ESI-LC/MS/MS method. The dose of 30 mg of gliquidone (1 tablet) was orally administered to 9 healthy Korean subjects. After administration, blood was taken at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 7, 9, 12, 24, and 33 hour. The validation data were as follows; the standard curve was linear ($r^2$=0.999) over the concentration range of $10\~1000 ng/ml$. The coefficient of variation for intra- and inter-day assay were $8.30\~18.86$, and $2.19\~12.92\%$, respectively. The lower limit of quantification for gliquidone was 10 ng/ml. The pharmacokinetic parameters obtained were as follows; $AUC_t$ was 3861.17$\pm$1328.61 ng-hr/ml, $C_{max}$ was 831.02$\pm$227.99 ng/ml, $T_{max}$ was $2.94{\pm}0.77 hr,\;K_e$, was 0.19$\pm$0.06 1/hr, and $t_{l/2}$ was 4.47$\pm$3.52 hr. Based on the validated analytical method and pharmacokinetic parameters, a standard guideline of the bioavailability test of gliquidone dosage forms was prepared successfully and could be used for the bioequivalence test of gliquidone preparation.
Keywords
electrospray tandem mass; gliquidone; bioavailability;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Kopitar, Z. and Koss, F. W. : Pharmacokinetic behavior of gliquidone (AR-DF 26), a new sulfonyl urea. Summary of the studies so far (author's transl). Arzneimittelforschung. 25(12), 1933 (1975)
2 Maurer, H. H., Kratzsch, C., Kraemer, T., Peters, F. T. and Weber, A. A. : Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylureatype in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. J. Chromatogr. B. 773(1), 63 (2002)   DOI   ScienceOn
3 Sener, A., Akkan, A. G. and Malaisse, W. J. : Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. Acta Diabetologica. 32(1), 64 (1995)   DOI   ScienceOn
4 Ferner, R. E. and Chaplin, S. : The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin. Pharmacokinetics. 12, 379 (1987)   DOI   ScienceOn
5 Courtois, P., Sener, A., Herbaut, C., Turc, A. and Malaisse, W. J. : Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged subjects. Res. Commun. Mol. Pathol. Pharmacal. 103(2), 211 (1999)
6 식품의약품안전청 고시 제2002호-60호, 생물학적동등성시험기준, 식품의약품안전청(2002. 11. 22.)
7 von Nicolai, H., Brickl, R., Eschey, H., Greischel, A., Heinzel, G., Konig, E., Limmer, J. and Rupprecht, E. : Duration of action and pharmaco-kinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. Arzneimittelforschung. 47(3), 247 (1997)